376 related articles for article (PubMed ID: 33902368)
1. Preferences for herpes zoster vaccination among adults aged 50 years and older in the United States: results from a discrete choice experiment.
Patterson BJ; Myers K; Stewart A; Mange B; Hillson EM; Poulos C
Expert Rev Vaccines; 2021 Jun; 20(6):729-741. PubMed ID: 33902368
[TBL] [Abstract][Full Text] [Related]
2. Immunization funding across 28 European countries.
Faivre P; Benčina G; Campbell R; Quilici S; Dauby N; Tešović G; Bonanni P; Drury R
Expert Rev Vaccines; 2021 Jun; 20(6):639-647. PubMed ID: 33759675
[TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy data for the recombinant zoster vaccine: impact on public health and cost effectiveness in Germany.
Curran D; Van Oorschot D; Matthews S; Hain J; Salem AE; Schwarz M
Hum Vaccin Immunother; 2021 Dec; 17(12):5296-5303. PubMed ID: 34905463
[TBL] [Abstract][Full Text] [Related]
4. A practitioner's guide to the recombinant zoster vaccine: review of national vaccination recommendations.
Parikh R; Widenmaier R; Lecrenier N
Expert Rev Vaccines; 2021 Sep; 20(9):1065-1075. PubMed ID: 34311643
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for herpes zoster: should people with asthma or COPD be vaccinated?
Safonova E; Yawn BP; Welte T; Wang C
Respir Res; 2023 Jan; 24(1):35. PubMed ID: 36709298
[TBL] [Abstract][Full Text] [Related]
6. Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults.
McGirr A; Van Oorschot D; Widenmaier R; Stokes M; Ganz ML; Jung H; Varghese L; Curran D
Appl Health Econ Health Policy; 2019 Oct; 17(5):723-732. PubMed ID: 31250218
[TBL] [Abstract][Full Text] [Related]
7. Budget-Impact Analysis of Alternative Herpes Zoster Vaccine Strategies: A U.S. HMO Perspective.
Graham J; Mauskopf J; Kawai K; Johnson KD; Xu R; Acosta CJ
J Manag Care Spec Pharm; 2016 Jul; 22(7):872-88. PubMed ID: 27348287
[TBL] [Abstract][Full Text] [Related]
8. Shingles vaccination uptake in Massachusetts adults aged 50 years and older.
Draper M; Stergiopoulos S
Vaccine; 2021 Nov; 39(46):6781-6786. PubMed ID: 34625290
[TBL] [Abstract][Full Text] [Related]
9. Factors influencing herpes zoster vaccination among older people in China: results from a discrete choice experiment.
Zhang H; Zhang LR; Chu LC; Sun X; Jiang XW
Public Health; 2023 Jul; 220():33-34. PubMed ID: 37263175
[TBL] [Abstract][Full Text] [Related]
10. Public health impact of recombinant zoster vaccine for prevention of herpes zoster in US adults immunocompromised due to cancer.
Curran D; Patterson BJ; Carrico J; Salem A; La EM; Lorenc S; Hicks KA; Poston S; Carpenter CF
Hum Vaccin Immunother; 2023 Dec; 19(1):2167907. PubMed ID: 36880669
[TBL] [Abstract][Full Text] [Related]
11. Herpes zoster vaccination among adults aged 60 years or older in the United States, 2007: uptake of the first new vaccine to target seniors.
Lu PJ; Euler GL; Jumaan AO; Harpaz R
Vaccine; 2009 Feb; 27(6):882-7. PubMed ID: 19071175
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
Hornberger J; Robertus K
Ann Intern Med; 2006 Sep; 145(5):317-25. PubMed ID: 16954357
[TBL] [Abstract][Full Text] [Related]
13. A systematic literature review to assess the burden of herpes zoster disease in China.
Yin D; Van Oorschot D; Jiang N; Marijam A; Saha D; Wu Z; Tang H; Diaz-Decaro J; Watson P; Xie X; Ren Y; He Y; Feng Y
Expert Rev Anti Infect Ther; 2021 Feb; 19(2):165-179. PubMed ID: 32997550
[TBL] [Abstract][Full Text] [Related]
14. Willingness to Vaccinate Against Herpes Zoster and Its Associated Factors Across WHO Regions: Global Systematic Review and Meta-Analysis.
Wang Q; Yang L; Li L; Liu C; Jin H; Lin L
JMIR Public Health Surveill; 2023 Mar; 9():e43893. PubMed ID: 36892937
[TBL] [Abstract][Full Text] [Related]
15. Community and patient values for preventing herpes zoster.
Lieu TA; Ortega-Sanchez I; Ray GT; Rusinak D; Yih WK; Choo PW; Shui I; Kleinman K; Harpaz R; Prosser LA
Pharmacoeconomics; 2008; 26(3):235-49. PubMed ID: 18282017
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of the Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults.
Le P; Rothberg MB
JAMA Intern Med; 2018 Feb; 178(2):248-258. PubMed ID: 29297049
[TBL] [Abstract][Full Text] [Related]
17. Vaccination: a new option to reduce the burden of herpes zoster.
Mick G
Expert Rev Vaccines; 2010 Mar; 9(3 Suppl):31-5. PubMed ID: 20192716
[TBL] [Abstract][Full Text] [Related]
18. Herpes Zoster Ophthalmicus: Presentation, Complications, Treatment, and Prevention.
Litt J; Cunningham AL; Arnalich-Montiel F; Parikh R
Infect Dis Ther; 2024 Jun; ():. PubMed ID: 38834857
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
Pellissier JM; Brisson M; Levin MJ
Vaccine; 2007 Nov; 25(49):8326-37. PubMed ID: 17980938
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and Duration of Protection Provided by the Live-attenuated Herpes Zoster Vaccine in the Medicare Population Ages 65 Years and Older.
Izurieta HS; Wernecke M; Kelman J; Wong S; Forshee R; Pratt D; Lu Y; Sun Q; Jankosky C; Krause P; Worrall C; MaCurdy T; Harpaz R
Clin Infect Dis; 2017 Mar; 64(6):785-793. PubMed ID: 28362955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
